Is Gemcitabine and cisplatin induction chemotherapy superior in locoregionally advanced nasopharyngeal carcinoma?

To investigate the outcome of locoregionally advanced nasopharyngeal carcinoma [NPC] treated with induction chemotherapy followed by chemoradiotherapy. Between June 2005 and October 2007, 604 patients with locoregionally advanced NPC were analyzed, of whom 399 and 205 were treated with conventional radiotherapy and intensity-modulated radiotherapy [IMRT] respectively. Meanwhile, 153 patients received concurrent chemotherapy, and 520 were given induction chemotherapy. With a median follow-up time of 65 months, the 3-, and 5-year overall survival [OS], locoregional free survival [LRFS], and distant-metastasis free survival [DMFS] rates were 82.5% vs. 72.6%, 90.6% vs. 87.1%, and 82.5% vs. 81.2%, respectively. Induction chemotherapy was not an independent prognostic factor for OS [P=0.193] or LRFS, but there was a positive tendency for DMFS [P=0.088]. GP regimen [gemcitabine + cisplatin] was an independent prognostic factor for OS [P = 0.038] and it had a trend toward improved DMFS [P = 0.109]. TP regimen [taxol + cisplatin] was only a significant prognostic factor for DMFS [P =0.038]. Adding induction chemotherapy had no survival benefit, but GP regimen benefited overall survival and had a trend toward improved DMFS. GP regimen may be superior to TP/FP regimen [fluorouracil + cisplatin] in treating locoregionally advanced NPC